111 related articles for article (PubMed ID: 16617563)
21. [Pulse inversion ultrasonography with ultrasonography contrast media (levovist) in the evaluation of hepatic metastasis].
Giovagnoni A; Martegani A; Aiani L; Ligabue G; Romagnoli R; Del Favero C
Radiol Med; 2001 Mar; 101(3):111-7. PubMed ID: 11402947
[TBL] [Abstract][Full Text] [Related]
22. [The usefulness of contrast-enhanced sonography in the differential diagnostic of adrenal tumors].
Słonina J; Nienartowicz E; Agrawal AK; Malczewska J; Moroń K
Endokrynol Pol; 2006; 57(3):230-6. PubMed ID: 16832787
[TBL] [Abstract][Full Text] [Related]
23. [Use of SHU 508 A Levovist contrast media in the characterization of solid lesions of the breast].
Guazzaroni M; Cossu E; Danese V; Montanaro M; Simonetti G
Radiol Med; 1998; 96(1-2):35-41. PubMed ID: 9819616
[TBL] [Abstract][Full Text] [Related]
24. Tumor vascularity of breast lesions: potentials and limits of contrast-enhanced Doppler sonography.
Stuhrmann M; Aronius R; Schietzel M
AJR Am J Roentgenol; 2000 Dec; 175(6):1585-9. PubMed ID: 11090380
[TBL] [Abstract][Full Text] [Related]
25. Late-phase pulse-inversion sonography using the contrast agent levovist: differentiation between benign and malignant focal lesions of the liver.
von Herbay A; Vogt C; Häussinger D
AJR Am J Roentgenol; 2002 Nov; 179(5):1273-9. PubMed ID: 12388513
[TBL] [Abstract][Full Text] [Related]
26. Value of contrast-enhanced power Doppler sonography using a microbubble echo-enhancing agent in evaluation of small breast lesions.
Kook SH; Kwag HJ
J Clin Ultrasound; 2003 Jun; 31(5):227-38. PubMed ID: 12767017
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of contrast-enhanced ultrasound for the differentiation of benign and malignant breast lesions.
Hu Q; Wang XY; Zhu SY; Kang LK; Xiao YJ; Zheng HY
Acta Radiol; 2015 Jan; 56(1):25-33. PubMed ID: 24436445
[TBL] [Abstract][Full Text] [Related]
28. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features.
Stomper PC; Herman S; Klippenstein DL; Winston JS; Edge SB; Arredondo MA; Mazurchuk RV; Blumenson LE
Radiology; 1995 Nov; 197(2):387-95. PubMed ID: 7480682
[TBL] [Abstract][Full Text] [Related]
29. Intravenous contrast ultrasound examination using contrast-tuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components.
Testa AC; Timmerman D; Van Belle V; Fruscella E; Van Holsbeke C; Savelli L; Ferrazzi E; Leone FP; Marret H; Tranquart F; Exacoustos C; Nazzaro G; Bokor D; Magri F; Van Huffel S; Ferrandina G; Valentin L
Ultrasound Obstet Gynecol; 2009 Dec; 34(6):699-710. PubMed ID: 19924735
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of benign and malignant breast tumors using Doppler spectral parameters including acceleration time index.
Mesaki K; Hisa N; Kubota K; Hisa N; Ogawa Y; Yoshida S
Oncol Rep; 2003; 10(4):945-50. PubMed ID: 12792750
[TBL] [Abstract][Full Text] [Related]
32. Sonographic evaluation of focal nodular hyperplasias (FNH) of the liver with a transpulmonary galactose-based contrast agent (Levovist).
Uggowitzer M; Kugler C; Gröll R; Mischinger HJ; Stacher R; Fickert P; Weiglein A
Br J Radiol; 1998 Oct; 71(850):1026-32. PubMed ID: 10211062
[TBL] [Abstract][Full Text] [Related]
33. Breast lesion characterization with contrast-enhanced US. Work in progress.
Caruso G; Ienzi R; Cirino A; Salvaggio G; Campione M; Lagalla R; Cardinale A
Radiol Med; 2002; 104(5-6):443-50. PubMed ID: 12589266
[TBL] [Abstract][Full Text] [Related]
34. The Italian experience with SH U 508 A (Levovist) in breast disease.
Spreafico C; Lanocita R; Frigerio LF; Di Tolla G; Garbagnati F; Milella M; Marchianò A; Piragine G; Damascelli B
Radiol Med; 1994 May; 87(5 Suppl 1):59-64. PubMed ID: 8209019
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of a US contrast agent in benign and malignant adnexal tumors.
Ordén MR; Jurvelin JS; Kirkinen PP
Radiology; 2003 Feb; 226(2):405-10. PubMed ID: 12563133
[TBL] [Abstract][Full Text] [Related]
36. Color doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist.
Ernst H; Hahn EG; Balzer T; Schlief R; Heyder N
J Clin Ultrasound; 1996 Jan; 24(1):31-5. PubMed ID: 8655665
[TBL] [Abstract][Full Text] [Related]
37. Color-doppler using contrast medium in evaluating the response to neoadjuvant treatment in patients with locally advanced breast carcinoma.
Vallone P; D'Angelo R; Filice S; Petrosino T; Rinaldo M; De Chiara A; Gallipoli A
Anticancer Res; 2005; 25(1B):595-9. PubMed ID: 15816633
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of dynamic susceptibility contrast MRI using echo-planar imaging in differential diagnosis of breast tumors].
Yoshino A
Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Jul; 58(8):441-6. PubMed ID: 9745258
[TBL] [Abstract][Full Text] [Related]
39. Comparing contrast-enhanced color flow imaging and pathological measures of breast lesion vascularity.
Forsberg F; Kuruvilla B; Pascua MB; Chaudhari MH; Merton DA; Palazzo JP; Goldberg BB
Ultrasound Med Biol; 2008 Sep; 34(9):1365-72. PubMed ID: 18436369
[TBL] [Abstract][Full Text] [Related]
40. Microbubble contrast agent for color Doppler US: effect on breast masses. Work in progress.
Kedar RP; Cosgrove D; McCready VR; Bamber JC; Carter ER
Radiology; 1996 Mar; 198(3):679-86. PubMed ID: 8628854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
